{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-13T19:51:31.829Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-13. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-13. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-13, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"ARQT\",\n  \"company\": \"Arcutis Biotherapeutics, Inc.\",\n  \"investigation_summary\": \"Arcutis is a commercial-stage dermatology biotech that has crossed into cash-flow positivity while posting 60%+ revenue growth on its ZORYVE (topical roflumilast) franchise. An sNDA for pediatric AD expansion (infants down to 3 months) was submitted in April 2026 and awaits FDA action — a material label expansion catalyst with only one competing non-steroidal option. All June 9 Form 4s were director RSU grants at $0 cost basis, not open-market purchases; no insider buying signal is present. Options flow shows a heavily bearish put/call ratio (4.17) on moderate volume, consistent with protective hedging by existing holders rather than new directional bets. The stock trades at ~21x forward P/E against 60%+ revenue growth — reasonable but not cheap — with analyst consensus near $35 vs current $24.38, implying the market has not fully priced in the pediatric label expansion upside or continued ZORYVE trajectory.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"cc\",\n    \"strangle\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"Arcutis Biotherapeutics is a commercial-stage biopharma focused on immuno-dermatology, anchored by the ZORYVE franchise (roflumilast in cream and foam formulations). ZORYVE 0.3% is approved for plaque psoriasis; ZORYVE 0.15% for rosacea; ZORYVE 0.05% for atopic dermatitis in patients down to age 6 years, with an sNDA pending to extend the AD indication to infants as young as 3 months — a segment affecting ~1 million U.S. children under age 2 with only one other FDA-approved non-steroidal option. Q1 2026 net product revenue was $105.4M (+65% YoY), and management reaffirmed full-year 2026 guidance of $480-495M in net product revenues. The company reached cash-flow positive status in 2025, a critical inflection point for a dermatology commercial-stage company historically dependent on dilutive financing. Balance sheet shows ~$224M cash against ~$115M debt — manageable. Gross margins are exceptional (~91%). The business is executing well; the question is whether near-term valuation leaves asymmetric upside or is fairly priced with limited room for re-rating.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 9157.75,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-05\",\n      \"recent_eps_surprise_pattern\": \"Mixed: Q3 2025 beat +164%, Q4 2025 beat +47%, but Q1 2026 missed by -55% (largely due to typical Q1 seasonality); forward estimates positive for Q2\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"sNDA submitted April 2026 seeking FDA approval to extend ZORYVE cream 0.05% AD indication to infants aged 3 months to <24 months — only one other non-steroidal topical exists in this segment, ~1M addressable patients, PDUFA timeline not yet specified\",\n          \"date_or_window\": \"FDA decision expected within standard 10-month review window (likely Q4 2026 or early 2027)\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-submits-supplemental-drug-application-120000919.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"INTEGUMENT-INFANT Phase 2 data presented at AAD Annual Meeting March 2026 showed well-tolerated safety profile in infants consistent with older populations; AAD issued strong recommendation for ZORYVE cream in first-ever pediatric AD guidelines (April 2026)\",\n          \"date_or_window\": \"March/April 2026 — already published, supports label expansion narrative\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-zoryve-roflumilast-cream-receives-120000398.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"Genital Psoriasis Wellness Consortium manuscript published June 2026 in American Journal of Clinical Dermatology — Arcutis supported, expands ZORYVE franchise narrative into a condition affecting ~2/3 of the 9M U.S. psoriasis patients; second publication from this consortium\",\n          \"date_or_window\": \"June 3, 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/expert-consensus-provides-age-specific-120000450.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"guidance\",\n          \"description\": \"Management reaffirmed full-year 2026 net product revenue guidance of $480M-$495M at Q1 earnings (May 6, 2026). Company declared cash-flow positive status.\",\n          \"date_or_window\": \"May 6 and April 14-15, 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-announces-first-quarter-2026-200000402.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 21.1,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": 538.2,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": 0.12,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"At ~$24 with a $3B market cap, ARQT trades at 21x forward P/E for a company growing revenue 60%+ annually that just reached cash-flow positivity — a reasonable but not cheap multiple relative to the sector. Analyst consensus target of $34.63 implies ~42% upside from current levels. The stock is near (but below) its 52-week high of $31.77, having pulled back from late-2025 peaks in tandem with broader small-cap biotech weakness. Valuation gap vs. analyst targets could close on successful pediatric label expansion or continued revenue beats.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"gross_margin_91pct\": 0.90942,\n      \"net_debt_to_ebitda\": \"improving - reached cash flow positive in 2025\",\n      \"balance_sheet_grade\": \"B+\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 57,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    },\n    \"price_context\": {\n      \"last_close\": 24.38,\n      \"ytd_return_pct\": 23.38,\n      \"from_52w_high_pct\": -23.3\n    },\n    \"filings_reviewed\": [\n      {\n        \"form\": \"10-K\",\n        \"filed\": \"2026-02-25\",\n        \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm\",\n        \"key_takeaways\": [\n          \"FY2025 revenue ~$416M, +60% YoY. Four ZORYVE products commercialized: cream 0.3%, cream 0.15%, cream 0.05%, foam. sNDA for infant AD pending as of filing date. Reached cash-flow positive in 2025 — major milestone. Gross margin ~91%. Net loss significantly narrowed vs prior year. AstraZeneca royalty obligations on patents (no material concern). No going-concern opinion despite historically needing financing.\"\n        ]\n      },\n      {\n        \"form\": \"8-K\",\n        \"filed\": \"2026-06-09\",\n        \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/arqt-20260605.htm\",\n        \"key_takeaways\": [\n          \"Annual meeting June 5, 2026: all three director proposals passed. Revised non-employee director compensation program approved. No material corporate governance concerns.\"\n        ]\n      },\n      {\n        \"form\": \"8-K (Q1 results)\",\n        \"filed\": \"2026-05-06\",\n        \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000039/arqt-20260506.htm\",\n        \"key_takeaways\": [\n          \"Q1 2026 net product revenue $105.4M (+65% YoY). Reaffirmed full-year guidance of $480-$495M. sNDA submission for infant AD (3 months to <24 months) noted as key near-term catalyst.\"\n        ]\n      },\n      {\n        \"form\": \"10-Q\",\n        \"filed\": \"2026-02-25\",\n        \"url\": null,\n        \"key_takeaways\": [\n          \"Q4 2025 EPS beat: actual $0.13 vs estimate $0.089 (+47%). Revenue and guidance confirm continued ZORYVE growth trajectory.\"\n        ]\n      }\n    ],\n    \"options_context\": {\n      \"expiries_examined\": [\n        \"2026-07-17\",\n        \"2026-09-18\",\n        \"2026-12-18\"\n      ],\n      \"iv_summary\": \"ATM IV on Sep 18 expiry (~96 DTE) approximately 60-70%; ATM puts show higher IV (0.95 for deep ITM $20 put vs. 0.66 for OTM call). Put skew present but not extreme.\",\n      \"notable_skew_or_flow\": \"Options flow shows a heavily bearish net dollar bias (-$6,480, -64.7%) with put/call ratio of 4.17 on near-term (Jul 17) expiry — this is consistent with protective hedging rather than directional speculative bears; the Sep 18 chain has high OTM call interest at $27.5 strike (306 contracts), which could represent covered-call writing or bull risk reversals by hedgers. ATM IV elevated enough to support CC or strangle premium collection.\"\n    },\n    \"competitive_landscape\": \"Arcutis competes in topical dermatology against giants like LEO Pharma, Ortho Dermatologics (Baush Health), and Pfizer's dermatology franchise. ZORYVE's differentiation is steroid-free PDE4 inhibition with once-daily dosing across multiple indications. The pediatric AD space has very limited competition — only one other non-steroidal option approved for infants under 2 years, giving Arcutis a meaningful first-mover advantage if the sNDA is approved.\",\n    \"key_risks\": [\n      \"sNDA approval timing and scope: FDA may not approve infant expansion on expected timeline or may require additional data\",\n      \"Revenue concentration in ZORYVE franchise — pipeline beyond roflumilast topical is early-stage (ARQ-234 checkpoint agonist)\",\n      \"Biotech commercial execution risk: payer coverage negotiations, prescriber adoption curves\",\n      \"The stock nearly doubled from ~$12.97 low to $31.77 high in late 2025 before pulling back; current level at $24 still represents significant recent appreciation that may limit near-term upside without new positive catalysts\",\n      \"Q1 2026 EPS miss (-55%) shows quarterly volatility and seasonality patterns can cause negative prints even during strong revenue growth\"\n    ],\n    \"what_the_market_might_be_missing\": \"The market may not be fully pricing in the pediatric AD label expansion opportunity. The AAD's April 2026 strong recommendation (first-ever pediatric AD guidelines) for ZORYVE cream, combined with only one competing non-steroidal option available for infants under 2 years, creates a potential exclusivity window worth ~$100-150M in incremental annual revenue if the sNDA is approved. Analyst consensus at $35 vs current $24 represents 40%+ upside that could be realized if Q2 earnings confirm continued trajectory and/or FDA approval timeline clarifies.\",\n    \"anti_signals_present\": [\n      \"dilution — historical ATM equity offerings to fund operations; while cash-flow positive now, debt of ~$115M remains\",\n      \"concentration — ZORYVE franchise is essentially the entire revenue base\"\n    ],\n    \"sources\": [\n      {\n        \"label\": \"Fundamentals / price data\",\n        \"url\": \"internal — yfinance via fundamentals() and price_history()\"\n      },\n      {\n        \"label\": \"10-K FY2025\",\n        \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm\"\n      },\n      {\n        \"label\": \"June 9 8-K (Annual Meeting)\",\n        \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/arqt-20260605.htm\"\n      },\n      {\n        \"label\": \"Q1 2026 results / sNDA announcement\",\n        \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-announces-first-quarter-2026-200000402.html\"\n      },\n      {\n        \"label\": \"AAD pediatric AD guideline recommendation\",\n        \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-zoryve-roflumilast-cream-receives-120000398.html\"\n      },\n      {\n        \"label\": \"sNDA submission for infant AD expansion\",\n        \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-submits-supplemental-drug-application-120000919.html\"\n      },\n      {\n        \"label\": \"Genital psoriasis wellness consortium publication\",\n        \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/expert-consensus-provides-age-specific-120000450.html\"\n      }\n    ],\n    \"unfetched_signals\": [\n      \"13f_deltas\",\n      \"politician_trades\",\n      \"sentiment_score\"\n    ]\n  }\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-13T19:52:34.236Z",
      "raw_content": "<think>The dossier is for ARQT (Arcutis Biotherapeutics, Inc.), a commercial-stage dermatology biotech.\nScout verdict: `range_bound_or_income`\nStructure hints: `cc`, `strangle`, `csp`\nMarket cap: ~$3B (implied by context, score as \"core\" since >$5B? Wait, $3B is < $5B, so \"asymmetric\" per the rubric: \"market_cap ≤ $5B (small-cap moonshot)\". Actually, the rubric says: \"core — market_cap > $5B\", \"asymmetric — market_cap ≤ $5B\". So ARQT is asymmetric.\nWait, $3B is large for a small-cap, but the rubric strictly says ≤ $5B is asymmetric. I will follow the rubric strictly.\nLet's score it.\n\nA. SMART-MONEY CLUSTER (max 25)\n- No insider purchases. 0 pts.\n- Material insider selling > 0? $9,157.75, negligible. No penalty.\n- Score: 0\n\nB. OPTIONS FLOW / UOA (max 10)\n- Put/call ratio 4.17, bearish net dollar bias (-64.7%). Consistent with hedging.\n- No whale call blocks.\n- Score: 0\n\nC. CATALYST (max 25)\n- Next earnings: 2026-08-05 (within 90 days). EPS surprise pattern: Mixed (Q3 beat, Q4 beat, Q1 miss). Doesn't meet \">0% last 4 quarters\". 0 pts.\n- Pending product launch / FDA: sNDA submitted April 2026 for infant AD. PDUFA not specified, but standard review is 10 months. Not a fixed PDUFA date, but a regulatory catalyst. Let's give 5 pts for pending regulatory milestone.\n- Recent guidance raise: Reaffirmed guidance, not raise. 0 pts.\n- Quantifiable sector tailwind: AAD guideline recommendation. Maybe 2 pts? Or stick to 5 for regulatory.\n- Cap at 25. I'll give 5 pts for regulatory catalyst.\n\nD. MISPRICING (max 15)\n- Forward P/E: 21.1. Sector median null. Not cheap relative to 60% growth? \"reasonable but not cheap\". 0 pts.\n- EV/EBITDA: 538.2. 0 pts.\n- FCF yield: 0.12%. 0 pts.\n- SOTP gap: null.\n- Score: 0\n\nE. QUALITY (max 15)\n- ROIC: null. 0 pts.\n- Gross margin: 91%, expanding? Not specified YoY trend, but high. 0 pts.\n- Net debt/EBITDA: improving, cash flow positive. 0 pts.\n- Score: 0\n\nF. MOMENTUM/TECHNICAL (max 10)\n- Above 50DMA and 200DMA: +3 pts.\n- 12-1 momentum: null. 0 pts.\n- RSI 14: 57 (in 40-65). +2 pts.\n- MACD: false. 0 pts.\n- Score: 5\n\nTotal Score: 10/100.\nWait, let's be generous but accurate. Maybe Catalyst gets 8 pts for FDA/sNDA. Technical gets 5. Total ~13.\nAnti-signals present: \"dilution — historical ATM equity offerings\", \"concentration — ZORYVE franchise is essentially the entire revenue base\". These are standard biotech risks, not hard gates unless >30% customer concentration (not mentioned, it's product concentration) or dilution >10% float (not specified, just \"historical ATM\").\nThe score is very low. The dossier explicitly says \"verdict: range_bound_or_income\", \"options flow shows heavily bearish put/call ratio\", \"no insider buying\", \"valuation not cheap\".\nEdge check: \"What does this idea say that the market doesn't already know?\" The market knows the sNDA is pending. The analyst target is $35 (42% upside). But the dossier says \"reasonable but not cheap\", \"stock pulled back from peaks\", \"Q1 miss\".\nGiven the low score (<45), the default is SKIP.\nI will output a skip.\n\nLet's calculate scores carefully per rubric:\nA: 0\nB: 0\nC: 8 (regulatory catalyst)\nD: 0\nE: 0\nF: 5 (above 50/200DMA, RSI 40-65)\nTotal: 13.\n\nReason for skip: Score is well below the 45 threshold. The dossier itself flags range-bound/income structure preference, lacks insider buying or asymmetric option flow, and notes valuation is not cheap relative to growth. The anti-signal of revenue concentration and historical dilution further limits conviction. No high-conviction thesis emerges.\n\nI will format the skip JSON.\nCheck risk class: market cap ~$3B -> asymmetric. Thresholds for asymmetric <45 is Skip.\nOutput matches skip format.\nAll good.\nProceed. \nLet's double check the exact JSON structure required for skip.\n{\n  \"skip\": true,\n  \"score\": <num>,\n  \"score_breakdown\": { ... },\n  \"reason\": \"...\"\n}\nReady. \nI will produce exactly that. \nOne minor point: The prompt says \"market_cap ≤ $5B (small-cap moonshot)\" for asymmetric. I'll stick with that. Score is 13. Skip.\nOutput matches request.\nDone. \nGenerating. \n(Self-Correction/Refinement during thought)\nWait, should I consider the strangle/CC structure? The prompt says: \"Even when Scout says 'no asymmetric long opportunity exists' (verdict=range_bound_or_income), there may be a clear INCOME structure... Don't reflex-skip just because long_stock isn't attractive.\"\nHowever, the score is 13. The thresholds for paper-tracking are 45-59. For <45, it says \"Skip\". The rubric is strict on thresholds. I will skip. The edge is weak, and the anti-signals (dilution, concentration) are present. The premium environment (IV 60-70%) might support a strangle, but the dossier lacks the specific strike/premium data to compute it safely, and the overall conviction is too low for publication or paper-tracking. I'll stick with skip.\nScore breakdown: A:0, B:0, C:8, D:0, E:0, F:5. Total: 13.\nReason: \"Score falls well below the 45-point threshold due to zero smart-money or mispricing signals, lack of sustained bullish options flow, and unproven catalyst timing. The dossier itself notes a range-bound setup with revenue concentration and historical dilution risks, making it unsuitable for publication or paper-tracking at this time.\"\nMatches requirements. Output matches exactly.✅\nProceeds. \nOutput Generation. \n[Done] \n```json\n{\n  \"skip\": true,\n  \"score\": 13,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Score falls well below the 45-point threshold due to zero smart-money or mispricing signals, lack of sustained bullish options flow, and unproven catalyst timing. The dossier explicitly flags a range-bound setup with revenue concentration and historical dilution risks, making it unsuitable for publication or paper-tracking at this time.\"\n}\n```\nWait, let's verify the rubric for C catalyst: \"8 pts: pending product launch / FDA / contract milestone in horizon\". sNDA submitted April 2026. PDUFA not specified. I'll give 8.\nTechnical: \"3 pts: above both 50DMA and 200DMA\", \"2 pts: RSI 14 in 40-65 zone\". Total 5.\nTotal 13. Correct.\nAll constraints met. Output matches exactly.\nProceeds. \n(Self-Correction/Note during generation prep)\nI will ensure the JSON is strictly valid and matches the prompt's skip schema.\nDone. \nOutput matches. \n[Final Check of the Prompt]\n\"IF YOU SKIP — output exactly: { \"skip\": true, \"score\": <0-100 composite>, \"score_breakdown\": {...}, \"reason\": \"...\" }\"\nAll good. \nProceeds. \n[Output Generation] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 13,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Score falls well below the 45-point threshold due to zero smart-money or mispricing signals, lack of sustained bullish options flow, and unproven catalyst timing. The dossier explicitly flags a range-bound setup with revenue concentration and historical dilution risks, making it unsuitable for publication or paper-tracking at this time.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 13,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Score falls well below the 45-point threshold due to zero smart-money or mispricing signals, lack of sustained bullish options flow, and unproven catalyst timing. The dossier explicitly flags a range-bound setup with revenue concentration and historical dilution risks, making it unsuitable for publication or paper-tracking at this time.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 13,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Score falls well below the 45-point threshold due to zero smart-money or mispricing signals, lack of sustained bullish options flow, and unproven catalyst timing. The dossier explicitly flags a range-bound setup with revenue concentration and historical dilution risks, making it unsuitable for publication or paper-tracking at this time.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 62408,
  "stop_reason": "stop",
  "completed_at": "2026-06-13T19:52:34.237Z"
}